Undisclosed ALK inhibitor / Sareum - LARVOL DELTA

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers - Episode 3 Considering the Role of NRG1 Fusions in Lung Cancer Management (Cancer Network) - "What does this tell us about the role of NRG1 fusions in lung cancer and the effectiveness of standard treatment strategies that harbor these NRG1 fusions, if anything?....I think that's fair. There are some ongoing studies with some newer agents, as well as some drugs that were tried that unfortunately did not appear to work at first glance. It would be great, now that we have these new patients in the database, to look at some of these because you'll have access to their charts and their records. They're probably a little bit more comprehensive in a prospective fashion as well as modern fashion...D. Ross Camidge, MD, PhD: I have to give a lecture to a country that shall not be named but is in the third world, and I have to talk to them about ALK inhibitors. They don't do any ALK testing in the entire country, and the reason is simple. They didn't have any licensed drugs until this year."

Video